Evidence Table 77. KQ2—Continuous data—High-density lipoprotein cholesterol (HDL-C)

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD /****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bays 20106parallel | Unclear | atorvastatin | 10-40 | Omega-3 (EPA, DHA, or both).  | 122 |  | Mean: Median 39.8SD: 34SE:48Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:2.4Median:SD:P:<0.001 |  | medium |
|  |  Placebo | 121 | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Bays 20106 parallel | Unclear | atorvastatin | 10-40 | Omega-3 (EPA, DHA, or both).  | 122 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:6.3Median:SD:P:0.001 |  | medium |
|  |  Placebo | 121 | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |

| Evidence Table 77. KQ2—Continuous data—High-density lipoprotein cholesterol (HDL-C) (continued) |
| --- |
| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD /****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Mabuchi 200739 parallel | Unclear | atorvastatin | 1 | Coenzyme Q10.  | 24 |  | Mean: 1.74Median SD: 0.42SE:Lower: Upper: | Mean:% mean: Median:SD:P:0.0033 | Mean:Median:SD:P: | "...no significant differences between the groups" | medium |
|  |  Placebo | 25 | Mean:1.61Median SD: 0.34SE:Lower: Upper: | Mean:Median:SD:P:0.0583 |
| Young 200770 parallel | Mod and high risk | simvastatinstatin | 10-40 | Coenzyme Q10. | 22 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P:0.65 | No difference in groups (p=0.65) | medium |
|  |  Placebo | 22 | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Davidson 200714 parallel | Unclear | simvastatinstatin | 40 | Omega-3 (EPA, DHA, or both).  | 122 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P:<0.001 |  | medium |
|  |  Placebo | 132 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean: -1.10Median:SD:P: |
| Meyer 200746 parallel | Unclear | simvastatinstatin | 81 | Fish/marine oils.  | 13 |  | Mean: 1.16Median SD: SE:0.09Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Fish/marine oils. 8g/d | 13 | Mean: 1.21Median SD: SE:0.05Lower: Upper: | Mean:% mean: Median:SD:P: |
|  | Placebo | 14 | Mean:1.11Median SD: SE:0.10Lower: Upper: | Mean:Median:SD:P: |
| Sutken 200663 parallel | Low and/or Moderate | Gemfibrozil | 1200 | Vitamin E.  | 22 |  | Mean: 0.82Median SD: SE:0.04Lower: Upper: | Mean:% mean: Median:SD:P:<0.05 | Mean:Median:SD:P: |  | high |
|  | Placebo | 23 | Mean:0.82Median SD: SE:0.04Lower: Upper: | Mean:Median:SD:P:<0.05 |
| Sutken 200663 parallel | Low and/or Moderate | Gemfibrozil | 1200 | Vitamin E.  | 12 |  | Mean: 1.57Median SD: SE:0.04Lower: Upper: | Mean:% mean: Median:SD:P:<0.01 | Mean:Median:SD:P: |  | high |
|  |  Placebo | 10 | Mean:1.41Median SD: SE:0.08Lower: Upper: | Mean:Median:SD:P:<0.01 |
| Macan 200640 parallel | Low and/or Moderate | Warfarin | NR | Garlic.  | 22 |  | Mean: Median SD: SE:Lower: Upper: | Mean:2.9% mean: Median:SD:7.9P: | Mean:Median:SD:P:0.038 | Other continous outcome assessed in this study: hemoglobin (weight also but I stated this in another comment as well) | medium |
|  | Placebo | 26 | Mean:Median SD: SE:Lower: Upper: | Mean:-1.6Median:SD:6.7P: |
| Manuel 200442 parallel | At high risk for CHD | Atorvastatin | 20 | Vitamin E.  | 11 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | Data not presented in paper - only provides baseline data per group and states that this outcome 'did not change in either group'. | medium |
|  | Placebo | 11 | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Playford 200358 parallel | At high risk for CHD | Fenofibrate | 200 | Coenzyme Q10. 200 mg plus 200 mg fenofibrate | 18 |  | Mean: 1.07Median SD: 0.05SE:Lower: Upper: | Mean:0.14% mean: Median:SD:P: | Mean:0.04 (group 1 vs. group 2Median:SD:P:0.385Mean:0.09(group 1 vs. group 3Median:SD:P:0.001 |  | low-medium |
|  | No treatment (aside from CVD drug) | 17 | Mean:1.11Median SD: SE:0.04Lower: Upper: | Mean:0.17Median:SD:P: |
|  | Coenzyme Q10. 200 mg CoQ10 only | 20 | Mean:0.98Median SD: SE:0.04Lower: Upper: | Mean:0.03Median:SD:P: |
|  | Placebo | 18 | Mean:0.98Median SD: SE:0.04Lower: Upper: | Mean:-0.05Median:SD:P: |
| Svaneborg 200264 parallel | At low risk for CHD (0-1 risk factors) | ASA | 100 | Omega-3 (EPA, DHA, or both).  | 12 |  | Mean: Median 1.18SD: 0.73SE:1.38Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | placebo= corn oil containing omega-6 | medium |
|  | Placebo | 6 | Mean:1.05Median SD: SE:Lower: 0.88Upper:1.45 | Mean:Median:SD:P: |
| Duffy 200120 parallel | Low and/or Moderate | simvastatinstatin | 10-40 | Vitamin E1000 IU vitmain E plus simvastatin | 6 |  | Mean: 1.4Median SD: 0.4SE:Lower: Upper: | Mean:-0.1% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
| No treatment (aside from CVD drug) | 7 | Mean:1.3Median SD: 0.3SE:Lower: Upper: | Mean:0Median:SD:P: |
|  1000IU Vitamin E | 6 |  | Mean:1.4Median SD: 0.3SE:Lower: Upper: | Mean:0.1Median:SD:P: |  |  |  |
| Placebo | 7 |  | Mean:Median SD: SE:Lower: Upper: | Mean-0.1Median:SD:P: |  |  |  |
| Napoli 199852 parallel | Unclear | Pravastatin | 20-40 | Vitamin E.  | 52 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: 9Median:SD:3%P:<0.05 | Mean:Median:SD:P: | Data not extracted but also available for VLDL-C, IDL-C, ApoB, Apo AI, Apo AII. Further, data not reported for routine laboratory tests and adverse effects. For these outcomes it is reported that “no differences in routine laboratory tests and adverse effects were registered during the study (data not shown); in particular, there were no differences between the values recorded in each individual after treatment compared with baseline values, and no differences between the treatment groups. | medium |
|  | No treatment (aside from CVD drug) | 56 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean:10Median:SD:4%P:<0.05 |
| Bordia 19989 parallel | At high risk for CHD | Nitrates | NR | Garlic.  | 30 |  | Mean: 49.5Median SD: SE:1.6Lower: Upper: | Mean:9% mean22.3: Median:SD:P:<0.05 | Mean:Median:SD:P: |  | high |
|  | Placebo | 30 | Mean:41.1Median SD: SE:2.8Lower: Upper: | Mean:0.1Median:SD:P: |
| Davidson 199715 parallel | Unclear | Simvastatinstatin | 10 | Fish/marine oils | 9 |  | Mean: 44.8Median SD: SE:3.5Lower: Upper: | Mean:4.5% mean: 10.4Median:SD:P:<0.05 | Mean:Median:SD:P: |  | Medium |
|  | No treatment (aside from CVD drug) | 10 | Mean:45.1Median SD: SE:2.9Lower: Upper: | Mean:2.7% mean 7.2Median:SD:P:<0.05 |
| Yamamoto 199569 parallel | At high risk for CHD | diltiazem | 90-120 | Omega-3 (EPA, DHA, or both).  | 12 |  | Mean: 45Median SD: SE:9Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | No treatment (aside from CVD drug) | 10 | Mean:47Median SD: SE:12Lower: Upper: | Mean:Median:SD:P: |
| McDowell 199444 parallel | Unclear | Simvastatinstatin | 20 | Vitamin E.  | 8 |  | Mean: 1.3Median SD: 0.3SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 8 | Mean:1.3Median SD: 0.4SE:Lower: Upper: | Mean:Median:SD:P: |
| Kaul 199234 parallel | At high risk for CHD | Calcium channel blocker, ASA | ASA: 150; heparin: 1000 U/d; ca blockers: NR | Fish/marine oils.  | 58 |  | Mean: 37Median SD: 10.5SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: |  | low-medium |
|  |  No treatment (aside from CVD drug) | 49 | Mean:37Median SD: 10.5SE:Lower: Upper: | Mean:Median:SD:P: |
| Nordøy 200355 parallel | Mod and high risk | atorvastatin | 10 | Fish/marine oils.  | 22 |  | Mean: Median SD: SE:Lower: Upper: | Mean:0.07% mean: Median:SD:0.08P: | Mean:Median:SD:P:0.03 |  | medium |
|  | Placebo | 20 | Mean:Median SD: SE:Lower: Upper: | Mean:0.01Median:SD:0.09P: |
| Roth 200960 parallel | Unclear | fenofibrates by 100% | 130 | Omega-3 (EPA, DHA, or both).  | 81 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median :-1.9SD:P: | Mean:Median:SD:P: | Not significant between groups | medium |
|  | Placebo | 82 | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Isley 200731 parallel | Unclear | niacin | 325 | Omega-3  | 7 |  | Mean: 49Median SD: 5SE:Lower: Upper: | Mean:% mean:33 Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 8 | Mean:48Median SD: 14SE:Lower: Upper: | Mean:% mean: 18Median:SD:P: |
| Budoff 200410 parallel | At high risk for CHD | statins + aspirin | 10-40 | Garlic | 9 |  | Mean: Median SD: SE:Lower: Upper: | Mean:3% mean: Median:SD:10.6P: | Mean:Median:SD:P:0.4611 |  | medium |
|  | Placebo | 10 | Mean:Median SD: SE:Lower: Upper: | Mean:-1.3Median:SD:13.8P: |
| Chan 200212 parallel | At moderate/moderately high risk for CHD (2+ risk factors) | atorvastatin | 40 | Fish/marine oils.  | 11 |  | Mean: 1.25Median SD: SE:0.09Lower: Upper: | Mean:% mean: 13.5Median:SD:3.80%P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 13 | Mean: 1.04Median SD: SE: 0.05Lower: Upper: | Mean:% mean:4.5Median:SD:P: |
| Liu 200337 parallel | Unclear | simvastatinstatin | 10 | Fish/marine oils.  | 19 |  | Mean: 1.53Median SD: 0.36SE:Lower: Upper: | Mean:0.11% mean: Median:SD:0.21P: | Mean:Median:SD:P: |  | medium |
|  | No treatment (aside from CVD drug) | 18 | Mean:1.77Median SD: 0.54SE:Lower: Upper:7.1 | Mean:0.12Median:SD:0.2P: |
| Dehmer 198817 parallel | At high risk for CHD | aspirin + Dipyridamole + ca channel blockers) | ASA: 325; dipyridamole: 225; Ca blocker: NR | Omega-3 (EPA, DHA, or both).  | 43 |  | Mean: 36Median SD: 8.7SE:Lower: Upper: | Mean:% mean:7.4 Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | No treatment (aside from CVD drug) | 39 | Mean:36Median SD: 9.4SE:Lower: Upper: | Mean:Median:SD:P: |
| Desideri 200318 parallel | At low risk for CHD (0-1 risk factors) | Simvastatinstatin, Bezafibrate | simvastatinstatin: 40; Bezafibrate: 800 | Vitamin E. |  |  | Mean: 1.2Median SD: 0.4SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | I assumed no losses to follow-up although I did not see this explicitely stated | medium |
|  | No treatment (aside from CVD drug) |  | Mean:1.1Median SD: 0.1SE:Lower: Upper: | Mean:Median:SD:P: |
| Wolf 200668crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba |  |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | Study states that: Laboratory findings in all subjects were un-remarkable and did not indicate any differences between the treatment groups. | low-medium |
|  |  |  | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| De Caterina 200216 crossover | At high risk for CHD | simvastatinstatin | 10-40 | Vitamin E |  |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | Values are presented in graphs, but difficult to read. Statement that "Neither LDL cholesterol nor triglycerides were affected by Vitamin E." | high |
|  | No treatment (aside from CVD drug) |  | Mean:54Median SD: 15.3SE:Lower: Upper: | Mean:2.2Median:SD:P: |
| Balestrieri 19964 crossover | Low and/or Moderate | Simvastatinstatin | 10-40 | Fish/marine oils | 14 |  | Mean: 53Median SD: 21SE:Lower: Upper: | Mean:2% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 14 | Mean:52Median SD: 18SE:Lower: Upper: | Mean:2Median:SD:P: |
| Paolisso 199556 crossover | At high risk for CHD | nifedipine | 88 | Vitamin E | 30 |  | Mean: 0.89Median SD: SE:0.04Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P:<0.05 |  | medium |
|  | Placebo | 30 | Mean:0.78Median SD: 0.07SE:Lower: Upper: | Mean:Median:SD:P: |
| Hansen199329 crossover | Low and/or Moderate | lovastatin | 40 | Fish/marine oils | 14 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: 6Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 14 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean:14Median:SD:P: |
| Mueller 199151 crossover | Low and/or Moderate | aspirin | 325-single dose | Fish/marine oils | 12 |  | Mean: 46.17Median SD: 11.56SE:Lower: Upper: | Mean:3.34% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 12 | Mean:44.25Median SD: 9.17SE:Lower: Upper: | Mean:1.42Median:SD:P: |
| Maki 200841 crossover | Low and/or Moderate | simvastatin | 20 | Omega-3  | 39 |  | Mean: Median 45SD: SE:Lower: 27Upper:106 | Mean:% mean: Median: 16.4%SD:P: | Mean:Median: 7.2SD:P:0.001 | The IQRs reported are actually ranges (low-high).  | medium |
|  | Placebo | 39 | Mean:Median 41SD: SE:Lower: 29Upper:93 | Mean:Median:10.6%SD:P: |